Case number 2018-1221
Nalpropion Pharmaceuticals v. Actavis Laboratories FL, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | NALPROPION PHARMACEUTICALS, v. ACTAVIS LABORATORIES FL, INC. [OPINION - PRECEDENTIAL] [precedential] (0) |
| May 26, 2020 | 117 | The petition for writ of certiorari, [19-1131], filed on 03/13/2020, was Denied on 05/26/2020. [696918] [JAB] [Entered: 05/26/2020 03:14 PM] (1) |
| Mar 18, 2020 | 116 | Petition for writ of Certiorari filed on 03/13/2020, and placed on the docket 03/16/2020, in the Supreme Court of the United States. Supreme Court #: 19-1131, Actavis Laboratories FL, Inc. v. Nalpropion Pharmaceuticals LLC. [679669] [JAB] [Entered: 03/18/2020 08:18 AM] (1) |
| Dec 30, 2019 | 115 | Amended Entry of appearance for Jaime A. Santos as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 12/30/2019 by email. [659610] [18-1221] [Jaime Santos] [Entered: 12/30/2019 05:44 PM] (2) |
| Dec 23, 2019 | 114 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [658401] [MJL] [Entered: 12/23/2019 09:39 AM] (1) |
| Dec 16, 2019 | 113 | ORDER filed denying combined petition for panel rehearing and rehearing en banc [85] filed by Actavis Laboratories FL, Inc. By: Per Curiam. Service as of this date by the Clerk of Court. [656684] [MJL] [Entered: 12/16/2019 10:28 AM] (2) |
| Nov 13, 2019 | 112 | ORDER filed granting motion to substitute party [109] filed by Appellee Nalpropion Pharmaceuticals, Inc. Appellee Nalpropion Pharmaceuticals, Inc. substituted by Appellee Nalpropion Pharmaceuticals LLC in 18-1221. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [648987] [JAB] [Entered: 11/13/2019 01:13 PM] (2) |
| Nov 12, 2019 | 111 | 18 paper copies of the response [110] received from Nalpropion Pharmaceuticals, Inc. [648502] [MJL] [Entered: 11/12/2019 09:50 AM] (0) |
| Nov 8, 2019 | 101 | Clerk's Note to the File: Amicus Curiae Association for Accessible Medicines must promptly file a certificate of interest as a separate docket entry in order to satisfy the requirements of Fed. Cir. R. 47.4(b). This filing is in addition to the COI included in the brief. [647985] [JAB] [Entered: 11/08/2019 08:56 AM] (0) |
| Nov 8, 2019 | 102 | Certificate of Interest for Amicus Curiae Association for Accessible Medicines. Service: 11/08/2019 by email. [648014] [18-1221] [Matthew Hellman] [Entered: 11/08/2019 09:49 AM] (2) |
| Nov 8, 2019 | 103 | Amended Entry of appearance for William M. Jay as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 11/08/2019 by email. [648190] [18-1221] [William Jay] [Entered: 11/08/2019 02:02 PM] (1) |
| Nov 8, 2019 | 104 | Corrected Certificate of Service filed by Appellant Actavis Laboratories FL, Inc. to Doc No. [103]. Service: 11/08/2019 by email. [648205] [18-1221] [William Jay] [Entered: 11/08/2019 02:24 PM] (1) |
| Nov 8, 2019 | 105 | Amended Entry of appearance for Dominick A. Conde as principal counsel for Nalpropion Pharmaceuticals LLC. Service: 11/08/2019 by email. [648337] [18-1221] [Joshua Calabro] [Entered: 11/08/2019 04:16 PM] (2) |
| Nov 8, 2019 | 106 | Amended Entry of appearance for Christopher P. Borello as of counsel for Nalpropion Pharmaceuticals LLC. Service: 11/08/2019 by email. [648338] [18-1221] [Joshua Calabro] [Entered: 11/08/2019 04:17 PM] (2) |
| Nov 8, 2019 | 107 | Amended Entry of appearance for Joshua D. Calabro as of counsel for Nalpropion Pharmaceuticals LLC. Service: 11/08/2019 by email. [648340] [18-1221] [Joshua Calabro] [Entered: 11/08/2019 04:18 PM] (2) |
| Nov 8, 2019 | 108 | Amended Entry of appearance for Zachary L. Garrett as of counsel for Nalpropion Pharmaceuticals LLC. Service: 11/08/2019 by email. [648342] [18-1221] [Joshua Calabro] [Entered: 11/08/2019 04:19 PM] (2) |
| Nov 8, 2019 | 109 | MOTION of Appellee Nalpropion Pharmaceuticals, Inc. to substitute party [Consent: unopposed]. Service: 11/08/2019 by email. [648348] [18-1221] [Dominick Conde] [Entered: 11/08/2019 04:26 PM] (15) |
| Nov 8, 2019 | 110 | RESPONSE from Nalpropion Pharmaceuticals LLC to the petition [85] filed by Appellant Actavis Laboratories FL, Inc., petition [85] filed by Appellant Actavis Laboratories FL, Inc.. Service: 11/08/2019 by email. [648355] [18-1221] [Dominick Conde] [Entered: 11/08/2019 04:34 PM] (24) |
| Nov 7, 2019 | 100 | 18 paper copies of the amicus Brief [99] received from Amicus Curiae Association for Accessible Medicines. [647691] [JAB] [Entered: 11/07/2019 11:19 AM] (0) |
| Nov 5, 2019 | 98 | ORDER filed granting motion leave to file amicus brief on en banc or rehearing petition [97]. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [647013] [JAB] [Entered: 11/05/2019 03:39 PM] (2) |
| Nov 5, 2019 | 99 | AMICUS BRIEF FILED on Petition for Association for Accessible Medicines. Pages: 14. Service: 10/30/2019 by email. The filer is directed to submit the appropriate number of copies within two days. [647016] [JAB] [Entered: 11/05/2019 03:41 PM] (21) |
| Oct 30, 2019 | 93 | Entry of appearance for Matthew S. Hellman as principal counsel for Association for Accessible Medicines. Service: 10/30/2019 by email. [645958] [18-1221] [Matthew Hellman] [Entered: 10/30/2019 04:17 PM] (2) |
| Oct 30, 2019 | 94 | Entry of appearance for Sara Tonnies Horton as of counsel for Association for Accessible Medicines. Service: 10/30/2019 by email. [645963] [18-1221] [Sara Horton] [Entered: 10/30/2019 04:23 PM] (2) |
| Oct 30, 2019 | 95 | Entry of appearance for Yusuf Esat as of counsel for Association for Accessible Medicines. Service: 10/30/2019 by email. [645969] [18-1221] [Yusuf Esat] [Entered: 10/30/2019 04:27 PM] (2) |
| Oct 30, 2019 | 96 | Entry of appearance for Jeffrey Francer as of counsel for Association for Accessible Medicines. Service: 10/30/2019 by email. [645975] [18-1221] [Jeffrey Francer] [Entered: 10/30/2019 04:32 PM] (2) |
| Oct 30, 2019 | 97 | MOTION of Association for Accessible Medicines for leave to file amicus brief in support of Appellant Actavis Laboratories FL, Inc. on petition [85], petition [85] [Consent: unopposed]. Service: 10/30/2019 by email. [645994] [18-1221] [Matthew Hellman] [Entered: 10/30/2019 05:00 PM] (30) |
| Oct 29, 2019 | 92 | 6 paper copies of the Supplemental Appendix Brief [88] received from Appellant Actavis Laboratories FL, Inc.. [645479] [CJF] [Entered: 10/29/2019 12:11 PM] (0) |
| Oct 28, 2019 | 91 | 6 paper copies of the Supplemental Appendix Brief [88] received from Appellant Actavis Laboratories FL, Inc.. [645347] [CJF] [Entered: 10/29/2019 08:53 AM] (0) |
| Oct 25, 2019 | 90 | The court invites a response from Appellee Nalpropion Pharmaceuticals, Inc. to the petition for panel rehearing, petition for en banc rehearing filed by Appellant in 18-1221. The response is due on or before 11/08/2019. [644802] [JAB] [Entered: 10/25/2019 01:36 PM] (1) |
| Oct 24, 2019 | 88 | MODIFIED ENTRY: APPENDIX FILED (SUPPLEMENTAL) for Actavis Laboratories FL, Inc. Number of Pages: 61. The filer is directed to submit the appropriate number of copies within two days. Service: 10/24/2019 by email. [644527] --[Edited 10/25/2019 by JAB - compliance review complete] [William Jay] [Entered: 10/24/2019 03:52 PM] (61) |
| Oct 24, 2019 | 89 | Corrected Certificate of Service filed by Appellant Actavis Laboratories FL, Inc. to Doc No. [88]. Service: 10/24/2019 by email. [644583] [18-1221] [William Jay] [Entered: 10/24/2019 05:12 PM] (1) |
| Oct 22, 2019 | 87 | ORDER filed. The motion [84] is granted, to the extent that the material contained in Volume III of the joint appendix is accepted. Actavis is directed to refile the material as a supplemental appendix on or before October 25, 2019. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [643941] [JAB] [Entered: 10/22/2019 03:17 PM] (2) |
| Oct 17, 2019 | 86 | 18 paper copies of the petition for en banc rehearing [85], petition for panel rehearing [85] received from Appellant Actavis Laboratories FL, Inc. [642923]--[Edited 10/25/2019 by JAB to correct docket text] [JAB] [Entered: 10/17/2019 03:01 PM] (0) |
| Oct 16, 2019 | 84 | MOTION of Appellant Actavis Laboratories FL, Inc. leave to file a supplemental appendix [Consent: not addressed]. Service: 10/16/2019 by email. [642730] [18-1221] [William Jay] [Entered: 10/16/2019 05:47 PM] (68) |
| Oct 16, 2019 | 85 | Petition for en banc rehearing, for panel rehearing filed by Appellant Actavis Laboratories FL, Inc. Service: 10/16/2019 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 10/18/2019 [642731] [18-1221]--[Edited 10/25/2019 by JAB to correct relief] [William Jay] [Entered: 10/16/2019 05:56 PM] (55) |
| Oct 3, 2019 | 81 | Entry of appearance for William M. Jay as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 10/03/2019 by email. [639933] [18-1221] [William Jay] [Entered: 10/03/2019 09:50 AM] (2) |
| Oct 3, 2019 | 82 | Entry of appearance for Alexandra D. Valenti as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 10/03/2019 by email. [639934] [18-1221] [Alexandra Valenti] [Entered: 10/03/2019 09:52 AM] (2) |
| Oct 3, 2019 | 83 | Entry of appearance for Jaime A. Santos as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 10/03/2019 by email. [639935] [18-1221] [Jaime Santos] [Entered: 10/03/2019 09:54 AM] (2) |
| Sep 12, 2019 | 80 | ORDER filed granting motion to extend time to file petition for rehearing en banc [79] filed by Actavis Laboratories FL, Inc. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [635092] [MJL] [Entered: 09/12/2019 01:37 PM] (2) |
| Sep 9, 2019 | 79 | MOTION of Appellant Actavis Laboratories FL, Inc. to extend the time to file a Petition for Rehearing En Banc until 10/16/2019 [Consent: unopposed]. Service: 09/09/2019 by email. [634103] [18-1221] [Jonathan Ball] [Entered: 09/09/2019 03:37 PM] (9) |
| Aug 15, 2019 | 77 | OPINION filed for the court by Prost, Chief Judge; Lourie, Circuit Judge and Wallach, Circuit Judge. Opinion dissenting in part filed by Chief Judge Prost. Denying as moot motion to strike document [54] filed by Appellee Nalpropion Pharmaceuticals, Inc.; Precedential Opinion. [628352] [JAB] [Entered: 08/15/2019 09:20 AM] (29) |
| Aug 15, 2019 | 78 | JUDGMENT. AFFIRMED-IN-PART AND REVERSED-IN-PART. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [628354] [JAB] [Entered: 08/15/2019 09:21 AM] (1) |
| May 9, 2019 | 76 | Submitted after ORAL ARGUMENT by Jonathan D. Ball, Ph.D. for Actavis Laboratories FL, Inc. and Mr. Dominick A. Conde for Nalpropion Pharmaceuticals, Inc. Panel: Judge: Prost , Judge: Lourie , Judge: Wallach. [606144] [JCP] [Entered: 05/09/2019 10:28 AM] (0) |
| May 7, 2019 | 75 | 6 paper copies of the Corrected Confidential Joint Appendix Brief (Vol. I - II) [74] received from Appellant Actavis Laboratories FL, Inc. and Appellee Nalpropion Pharmaceuticals, Inc.. [605430] [CJF] [Entered: 05/07/2019 10:21 AM] (0) |
| May 6, 2019 | 72 | Notice of Correction to the Brief Doc No. [40], appendix Brief Doc No. [40], confidential Brief Doc No. [41], appendix Brief Doc No. [41] for Appellant Actavis Laboratories FL, Inc.. Service: 05/06/2019 by email. [605347] [18-1221] [Jonathan Ball] [Entered: 05/06/2019 05:52 PM] (6) |
| May 6, 2019 | 73 | MODIFIED ENTRY: CORRECTED APPENDIX FILED for Actavis Laboratories FL, Inc. and Nalpropion Pharmaceuticals, Inc. Number of Pages: 1005. Service: 05/06/2019 by email. [605350]--[Edited 05/07/2019 by JAB - compliance review complete] [Jonathan Ball] [Entered: 05/06/2019 05:59 PM] (1005) |
| May 6, 2019 | 74 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL JOINT APPENDIX FILED for Actavis Laboratories FL, Inc. and Nalpropion Pharmaceuticals, Inc. Number of Pages: 1039. Service: 05/06/2019 by email. The paper copies of the corrected confidential appendix are due 05/08/2019. [605351]--[Edited 05/07/2019 by JAB - compliance review complete] [Jonathan Ball] [Entered: 05/06/2019 06:07 PM] (0) |
| Apr 15, 2019 | 70 | Response to notice of oral argument from the Appellee Nalpropion Pharmaceuticals, Inc.. [600142] [18-1221] [Dominick Conde] [Entered: 04/15/2019 01:41 PM] (3) |
| Apr 15, 2019 | 71 | Response to notice of oral argument from the Appellant Actavis Laboratories FL, Inc.. [600256] [18-1221] [Jonathan Ball] [Entered: 04/15/2019 04:02 PM] (3) |
| Mar 21, 2019 | 69 | NOTICE OF ORAL ARGUMENT. Panel: 1905J. Case scheduled May 09, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Response to Notice of Oral Argument due: 04/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [594634] [PBC] [Entered: 03/21/2019 03:08 PM] (2) |
| Feb 7, 2019 | 68 | 6 paper copies of the Corrected Supplemental Appendix Brief [66] received from Appellee Nalpropion Pharmaceuticals, Inc.. [584103] [CJF] [Entered: 02/07/2019 01:45 PM] (0) |
| Feb 6, 2019 | 67 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [583671] [MMA] [Entered: 02/06/2019 09:03 AM] (0) |
| Feb 1, 2019 | 66 | MODIFIED ENTRY: CORRECTED APPENDIX FILED (SUPPLEMENTAL) for Nalpropion Pharmaceuticals, Inc. Number of Pages: 6. Service: 02/01/2019 by email. [582628]--[Edited 02/05/2019 by MMA - Reason: compliance review complete] [Zachary Garrett] [Entered: 02/01/2019 09:06 AM] (6) |
| Jan 31, 2019 | 65 | NOTICE OF NON-COMPLIANCE: The submission of Appellee Nalpropion Pharmaceuticals, Inc., Supplemental Appendix [64], is not in compliance with the rules of this court (see attached). Compliant document due on 02/07/2019. Service as of this date by the Clerk of Court.[582394] [MMA] [Entered: 01/31/2019 12:48 PM] (1) |
| Jan 24, 2019 | 64 | FILED from Appellee Nalpropion Pharmaceuticals, Inc. Title: SUPPLEMENTAL APPENDIX. Service: 01/24/2019 by email. [580805] [18-1221]. This document is non-compliant. See Doc. No. [65] [Zachary Garrett] [Entered: 01/24/2019 05:53 PM] (5) |
| Jan 17, 2019 | 63 | ORDER filed. Actavis’s motion for leave to file an opposition [58] is granted. Nalpropion’s motion to strike [54] is deferred to the merits panel assigned to this appeal. A copy of the motion, opposition, reply, and this order shall be transmitted to the assigned merits panel. Within seven days from the date of this order, Nalpropion may file a supplemental appendix containing the rebuttal information, which shall also be transmitted to the merits panel. - FOR CALENDAR. (Per Curiam). Service: 01/17/2019 by clerk. [578952] [NL] [Entered: 01/17/2019 12:38 PM] (2) |
| Jan 2, 2019 | 60 | REPLY of Appellee Nalpropion Pharmaceuticals, Inc. to response filed by Appellant, Doc. No [59]. Service: 01/02/2019 by email. [575374] [18-1221] [Zachary Garrett] [Entered: 01/02/2019 03:48 PM] (15) |
| Dec 26, 2018 | 58 | MOTION of Appellant Actavis Laboratories FL, Inc. for leave to file a response/reply to [54] motion to strike document [Consent: opposed]. Service: 12/24/2018 by email. [574339] [18-1221] [Richard Pettus] [Entered: 12/24/2018 11:25 AM] (24) |
| Dec 26, 2018 | 59 | RESPONSE of Appellant Actavis Laboratories FL, Inc. to the motion [54] filed by Appellee Nalpropion Pharmaceuticals, Inc.. Service: 12/24/2018 by email. [574340] [18-1221] [Richard Pettus] [Entered: 12/24/2018 11:26 AM] (16) |
| Dec 21, 2018 | 56 | Notice from Appellant Actavis Laboratories FL, Inc. regarding conflicts with oral argument. Service: 12/21/2018 by email. [573968] [18-1221] [Jonathan Ball] [Entered: 12/21/2018 11:11 AM] (2) |
| Dec 21, 2018 | 57 | Notice from Appellee Nalpropion Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 12/21/2018 by email. [574055] [18-1221] [Zachary Garrett] [Entered: 12/21/2018 12:06 PM] (2) |
| Dec 18, 2018 | 55 | 6 paper copies of the Confidential Joint Appendix Brief (Vol. I - II) [41] received from Appellant Actavis Laboratories FL, Inc. and Appellee Nalpropion Pharmaceuticals, Inc.. [572630] [CJF] [Entered: 12/18/2018 11:51 AM] (0) |
| Dec 17, 2018 | 54 | MOTION of Appellee Nalpropion Pharmaceuticals, Inc. to strike Brief [39] [Consent: opposed]. Service: 12/17/2018 by email. [572393] [18-1221] [Zachary Garrett] [Entered: 12/17/2018 05:02 PM] (17) |
| Dec 14, 2018 | 52 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [571747] [JB] [Entered: 12/14/2018 09:34 AM] (0) |
| Dec 14, 2018 | 53 | Notice to Advise of Scheduling Conflicts. Please advise of any scheduling conflicts during the upcoming court session months listed in the attached Notice. The notice of conflict with oral argument is due on or before 12/21/2018. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [571748] [JB] [Entered: 12/14/2018 09:35 AM] (1) |
| Nov 29, 2018 | 51 | 6 paper copies of the Corrected Reply Brief [50] received from Appellant Actavis Laboratories FL, Inc.. [568550] [CJF] [Entered: 11/29/2018 12:57 PM] (0) |
| Nov 20, 2018 | 40 | MODIFIED ENTRY: APPENDIX FILED for Actavis Laboratories FL, Inc. and Nalpropion Pharmaceuticals, Inc. Number of Pages: 1005. Service: 11/20/2018 by email. [566927] --[Edited 12/14/2018 by JBR - compliance review complete] This appendix has been corrected. See Doc. No. [73]. [Jonathan Ball] [Entered: 11/20/2018 05:03 PM] (1005) |
| Nov 20, 2018 | 41 | MODIFIED ENTRY: CONFIDENTIAL JOINT APPENDIX FILED for Actavis Laboratories FL, Inc. and Nalpropion Pharmaceuticals, Inc. Number of Pages: 1039. Service: 11/20/2018 by email. [566932]--[Edited 12/14/2018 by JBR - compliance review complete] This appendix has been corrected. See Doc. No. [74]. [Jonathan Ball] [Entered: 11/20/2018 05:10 PM] (0) |
| Nov 20, 2018 | 42 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellant Actavis Laboratories FL, Inc. and Appellee Nalpropion Pharmaceuticals, Inc.. Service: 11/20/2018 by email. [566934] [18-1221] [Jonathan Ball] [Entered: 11/20/2018 05:11 PM] (3) |
| Nov 20, 2018 | 43 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Actavis Laboratories FL, Inc.. Service: 11/20/2018 by email. [566937] [18-1221] [Jonathan Ball] [Entered: 11/20/2018 05:14 PM] (3) |
| Nov 20, 2018 | 44 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellee Nalpropion Pharmaceuticals, Inc.. Service: 11/20/2018 by email. [566959] [18-1221] [Joshua Calabro] [Entered: 11/20/2018 06:45 PM] (4) |
| Nov 20, 2018 | 45 | Amended Entry of appearance for Dominick A. Conde as principal counsel for Appellee Nalpropion Pharmaceuticals, Inc.. Service: 11/20/2018 by email. [566960] [18-1221] [Joshua Calabro] [Entered: 11/20/2018 06:47 PM] (2) |
| Nov 20, 2018 | 46 | Amended Entry of appearance for Christopher P. Borello as of counsel for Appellee Nalpropion Pharmaceuticals, Inc.. Service: 11/20/2018 by email. [566961] [18-1221] [Joshua Calabro] [Entered: 11/20/2018 06:47 PM] (2) |
| Nov 20, 2018 | 47 | Amended Entry of appearance for Brendan M. O'Malley as of counsel for Appellee Nalpropion Pharmaceuticals, Inc.. Service: 11/20/2018 by email. [566962] [18-1221] [Joshua Calabro] [Entered: 11/20/2018 06:49 PM] (2) |
| Nov 20, 2018 | 48 | Amended Entry of appearance for Joshua D. Calabro as of counsel for Appellee Nalpropion Pharmaceuticals, Inc.. Service: 11/20/2018 by email. [566963] [18-1221] [Joshua Calabro] [Entered: 11/20/2018 06:49 PM] (2) |
| Nov 20, 2018 | 49 | Amended Entry of appearance for Zachary L. Garrett as of counsel for Appellee Nalpropion Pharmaceuticals, Inc.. Service: 11/20/2018 by email. [566964] [18-1221] [Joshua Calabro] [Entered: 11/20/2018 06:50 PM] (2) |
| Nov 15, 2018 | 38 | Notice of Correction to the Brief Doc No. [37] for Appellant Actavis Laboratories FL, Inc.. Service: 11/15/2018 by email. [565251] [18-1221] [Richard Pettus] [Entered: 11/15/2018 11:24 AM] (6) |
| Nov 15, 2018 | 39 | TENDERED from Appellant Actavis Laboratories FL, Inc.. Title: CORRECTED REPLY BRIEF. Service: 11/15/2018 by email. [565252] [18-1221] [Richard Pettus] [Entered: 11/15/2018 11:25 AM] (40) |
| Nov 15, 2018 | 50 | CORRECTED REPLY BRIEF FILED for Appellant Actavis Laboratories FL, Inc. [39]. Number of Pages: 31. Service: 11/13/2018 by email. Appendix is due 11/20/2018. [567951] [JB] [Entered: 11/27/2018 03:36 PM] (40) |
| Nov 13, 2018 | 37 | TENDERED from Appellant Actavis Laboratories FL, Inc.. Title: REPLY BRIEF. Service: 11/13/2018 by email. [564593] [18-1221] [Richard Pettus] [Entered: 11/13/2018 04:37 PM] (40) |
| Oct 15, 2018 | 36 | 6 paper copies of the Opening Response Brief [35] received from Appellee Nalpropion Pharmaceuticals, Inc.. [556900] [CJF] [Entered: 10/15/2018 09:41 AM] (0) |
| Sep 28, 2018 | 34 | TENDERED from Appellee Nalpropion Pharmaceuticals, Inc.. Title: RESPONSE BRIEF. Service: 09/28/2018 by email. [553444] [18-1221] [Dominick Conde] [Entered: 09/28/2018 06:37 PM] (75) |
| Sep 28, 2018 | 35 | BRIEF FILED for Appellee Nalpropion Pharmaceuticals, Inc. [34]. Number of Pages: 63. Service: 09/28/2018 by email. The paper copies of the brief should be received by the court on or before 10/19/2018. [556566] [JB] [Entered: 10/12/2018 09:44 AM] (75) |
| Sep 20, 2018 | 33 | Entry of appearance for Zachary L. Garrett as of counsel for Appellee Nalpropion Pharmaceuticals, Inc.. Service: 09/20/2018 by email. [551550] [18-1221] [Joshua Calabro] [Entered: 09/20/2018 06:55 PM] (2) |
| Sep 19, 2018 | 32 | ORDER filed. The motion to substitute [30] is granted. The revised official caption and short caption are reflected in the order. The motion to lift the stay and set a briefing schedule [31] is granted to the extent that Nalpropion’s response brief is due no later than September 28, 2018 and Actavis’ reply brief is due no later than November 13, 2018. Service: 09/19/2018 by clerk. [551050] [NL] [Entered: 09/19/2018 02:51 PM] (2) |
| Sep 5, 2018 | 31 | MOTION of Nalpropion Pharmaceuticals, Inc. to lift stay, to set briefing schedule [Consent: unopposed]. Service: 09/05/2018 by email. [547308] [18-1221] [Joshua Calabro] [Entered: 09/05/2018 12:11 PM] (15) |
| Aug 29, 2018 | 26 | Entry of appearance for Dominick A. Conde as principal counsel for Nalpropion Pharmaceuticals, Inc.. Service: 08/29/2018 by email. [546101] [18-1221] [Joshua Calabro] [Entered: 08/29/2018 12:55 PM] (2) |
| Aug 29, 2018 | 27 | Entry of appearance for Brendan M. O'Malley as of counsel for Nalpropion Pharmaceuticals, Inc.. Service: 08/29/2018 by email. [546103] [18-1221] [Joshua Calabro] [Entered: 08/29/2018 12:58 PM] (2) |
| Aug 29, 2018 | 28 | Entry of appearance for Christopher P. Borello as of counsel for Nalpropion Pharmaceuticals, Inc.. Service: 08/29/2018 by email. [546104] [18-1221] [Joshua Calabro] [Entered: 08/29/2018 01:00 PM] (2) |
| Aug 29, 2018 | 29 | Entry of appearance for Joshua D. Calabro as of counsel for Nalpropion Pharmaceuticals, Inc.. Service: 08/29/2018 by email. [546106] [18-1221] [Joshua Calabro] [Entered: 08/29/2018 01:02 PM] (2) |
| Aug 29, 2018 | 30 | MOTION of Nalpropion Pharmaceuticals, Inc. to substitute party [Consent: unopposed]. Service: 08/29/2018 by email. [546107] [18-1221] [Joshua Calabro] [Entered: 08/29/2018 01:05 PM] (10) |
| Jul 23, 2018 | 25 | Status report for Appellee Orexigen Therapeutics, Inc.. Service: 07/23/2018 by email. [537989] [18-1221] [Chad Peterman] [Entered: 07/23/2018 06:16 PM] (3) |
| Jul 11, 2018 | 24 | ORDER filed. The motion [23] is denied without prejudice to refiling. The stay is maintained. Orexigen remains directed to file a status report every 90 days and to inform the court within 21 days after the bankruptcy proceedings are completed or the automatic stay pursuant to 11 U.S.C. § 362 has been lifted. Service: 07/11/2018 by clerk. [535020] [LMS] [Entered: 07/11/2018 09:35 AM] (2) |
| Jun 28, 2018 | 22 | Notice of Rejection to Appellee Orexigen Therapeutics, Inc., the following document(s): motion for other relief [21]; motion to lift stay [20] is REJECTED for filing. Reason(s): see attached notice. Service: 06/28/2018 by clerk. [532556] [JB] [Entered: 06/28/2018 01:54 PM] (1) |
| Jun 28, 2018 | 23 | MOTION of Appellee Orexigen Therapeutics, Inc. to lift stay, to set briefing schedule [Consent: unopposed]. Service: 06/28/2018 by email. [532641] [18-1221] [Chad Peterman] [Entered: 06/28/2018 05:00 PM] (7) |
| Jun 27, 2018 | 20 | MOTION of Appellee Orexigen Therapeutics, Inc. to lift stay [Consent: unopposed]. Service: 06/27/2018 by email. [532303] [18-1221] [Chad Peterman] [Entered: 06/27/2018 02:04 PM] (6) |
| Jun 27, 2018 | 21 | MOTION of Appellee Orexigen Therapeutics, Inc. to Lift Stay and Set Briefing Schedule [Corrected District Court case number on caption] [Consent: unopposed]. Service: 06/27/2018 by email. [532306] [18-1221] [Chad Peterman] [Entered: 06/27/2018 02:39 PM] (6) |
| Apr 23, 2018 | 19 | ORDER filed. The appeal is stayed. Orexigen Therapeutics is directed to file a status report every 90 days and to inform the court within 21 days after the bankruptcy proceedings are completed or the automatic stay pursuant to 11 U.S.C. § 362 has been lifted. Service: 04/23/2018 by clerk. [516029] [LMS] [Entered: 04/23/2018 12:01 PM] (2) |
| Apr 10, 2018 | 18 | Notice regarding bankruptcy (Notice of Suggestion of Bankruptcy and Automatic Stay of Appeal) from Appellee Orexigen Therapeutics, Inc.. Service: 04/10/2018 by email. [512187] [18-1221] [Chad Peterman] [Entered: 04/10/2018 04:11 PM] (3) |
| Feb 26, 2018 | 17 | 6 paper copies of the Opening Brief [16] received from Appellant Actavis Laboratories FL, Inc. [500956] [SJL] [Entered: 02/26/2018 10:36 AM] (0) |
| Feb 21, 2018 | 15 | TENDERED from Appellant Actavis Laboratories FL, Inc.. Title: OPENING BRIEF. Service: 02/21/2018 by email. [499936] [Jonathan Ball] [Entered: 02/21/2018 04:13 PM] (215) |
| Feb 21, 2018 | 16 | BRIEF FILED for Appellant Actavis Laboratories FL, Inc. [15]. Number of Pages: 66. Service: 02/21/2018 by email. The paper copies of the brief should be received by the court on or before 03/01/2018. [500447] [JB] [Entered: 02/22/2018 04:11 PM] (215) |
| Jan 18, 2018 | 14 | ORDER filed. The motion [13] is granted. The appellant's opening brief is due no later than February 21, 2018. The appellee's response brief is due no later than May 2, 2018. The appellant's reply brief is due no later than May 16, 2018. Service: 01/18/2018 by clerk. [490624] [LMS] [Entered: 01/18/2018 10:42 AM] (2) |
| Jan 12, 2018 | 13 | MOTION of Appellant Actavis Laboratories FL, Inc. and Appellee Orexigen Therapeutics, Inc. to set briefing schedule. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/12/2018 by email. [489419] [Brian Prew] [Entered: 01/12/2018 03:48 PM] (11) |
| Jan 2, 2018 | 12 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a)and Fed. Cir. R. 47.3 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [486656] [JB] [Entered: 01/02/2018 02:26 PM] (0) |
| Dec 6, 2017 | 2 | Entry of appearance for Jonathan D. Ball as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 12/06/2017 by email. [480712] [Jonathan Ball] [Entered: 12/06/2017 03:28 PM] (2) |
| Dec 6, 2017 | 3 | Entry of appearance for Scott J. Bornstein as principal counsel for Appellant Actavis Laboratories FL, Inc.. Service: 12/06/2017 by email. [480714] [Jonathan Ball] [Entered: 12/06/2017 03:30 PM] (2) |
| Dec 6, 2017 | 4 | Entry of appearance for Justin A. Maclean as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 12/06/2017 by email. [480715] [Jonathan Ball] [Entered: 12/06/2017 03:31 PM] (2) |
| Dec 6, 2017 | 5 | Entry of appearance for Richard C. Pettus as of counsel for Appellant Actavis Laboratories FL, Inc.. Service: 12/06/2017 by email. [480721] [Jonathan Ball] [Entered: 12/06/2017 03:32 PM] (2) |
| Dec 6, 2017 | 6 | Certificate of Interest for the Appellant Actavis Laboratories FL, Inc.. Service: 12/06/2017 by email. [480724] [Jonathan Ball] [Entered: 12/06/2017 03:33 PM] (5) |
| Dec 6, 2017 | 7 | Docketing Statement for the Appellant Actavis Laboratories FL, Inc.. Service: 12/06/2017 by email. [480725] [Jonathan Ball] [Entered: 12/06/2017 03:34 PM] (5) |
| Dec 6, 2017 | 8 | Entry of appearance for Bruce M. Wexler as of counsel for Appellee Orexigen Therapeutics, Inc.. Service: 12/06/2017 by email. [480817] [Bruce Wexler] [Entered: 12/06/2017 07:10 PM] (2) |
| Dec 6, 2017 | 9 | Entry of appearance for Chad J. Peterman as principal counsel for Appellee Orexigen Therapeutics, Inc.. Service: 12/06/2017 by email. [480819] [Chad Peterman] [Entered: 12/06/2017 07:14 PM] (2) |
| Dec 6, 2017 | 10 | Certificate of Interest for the Appellee Orexigen Therapeutics, Inc.. Service: 12/06/2017 by email. [480822] [Chad Peterman] [Entered: 12/06/2017 07:20 PM] (3) |
| Dec 6, 2017 | 11 | Docketing Statement for the Appellee Orexigen Therapeutics, Inc.. Service: 12/06/2017 by email. [480824] [Chad Peterman] [Entered: 12/06/2017 07:23 PM] (6) |
| Nov 22, 2017 | 1 | Appeal docketed. Received: 11/22/2017. [477949]Entry of Appearance due 12/06/2017. Certificate of Interest is due on 12/06/2017. Docketing Statement due 12/06/2017. Appellant/Petitioner's brief is due 01/22/2018. [JB] [Entered: 11/22/2017 03:27 PM] (72) |
